You are here: Industry Insights > Ascletis

News List

Clinical Trial Application of ASC40 Combined with Bevacizumab to Treat Patients with Recurrent Glioblastoma Accepted by China NMPA prnasia
May 25, 2021
Ascletis Pharma Inc. today announces that following the consultation with China National Medical Products Administration (NMPA), the clinical trial application of ASC40 combined with bevacizumab to treat patients with recurrent glioblastoma (rGBM) has ...
Gannex Announces the First Cohort Dosed in a U.S. Clinical Study with THR-β Agonist ASC41 prnasia
April 15, 2021
Gannex, a wholly owned company of Ascletis Pharma Inc., fully dedicated to the R&D and commercialization of new drugs in the field of non-alcoholic steatohepatitis (NASH), announces the dosing of the first cohort in the U.S. Phase I clinical study of ...
Ascletis Announces Investment Escalation in R&D of Cancer Lipid Metabolism and Oral Checkpoint Inhibitors prnasia
March 30, 2021
Ascletis Pharma Inc. announces today that the board of directors of the Company has resolved to deploy more resources and investment in the R&D of cancer lipid metabolism and oral checkpoint inhibitors.
FASN Inhibitor ASC40 Demonstrates Positive Phase 2 Topline Clinical Results from China Cohort of Patients with NASH prnasia
March 09, 2021
Gannex Pharma Co., Ltd., a wholly-owned company of Ascletis Pharma Inc., and Sagimet Biosciences Inc. jointly announced today positive topline results from the China cohort of a Phase 2 randomized, placebo-controlled clinical trial of oral ...
Gannex Announces Positive Clinical Results in Overweight and Obese Subjects for Its THR-β Agonist ASC41 prnasia
February 22, 2021
Gannex announces the positive clinical results in overweight and obese subjects for ASC41, a liver-targeted prodrug. The active metabolite of ASC41 is a selective thyroid hormone receptor beta (THR-β) agonist.
Gannex Announces Positive Phase I Clinical Results on Its THR-β Agonist ASC41 prnasia
January 12, 2021
Gannex, a wholly owned company of Ascletis Pharma Inc. and fully dedicated to the R&D and commercialization of new drugs in the field of non-alcoholic steatohepatitis (NASH), today announces the positive phase I clinical results of ASC41 oral tablet ...
First Subject Dosed with Gannex's FXR Agonist ASC42 in a U.S. Phase I Trial prnasia
December 28, 2020
Gannex announces today dosing of first subject with its NASH drug candidate ASC42, a Farnesoid X Receptor (FXR) agonist, in a U.S. Phase I Trial.
Overweight and Obese Subjects Dosed with ASC41 Tablets in a Phase Ib Trial prnasia
December 22, 2020
Gannex announces today dosing of overweight and obese subjects in a Phase Ib trial of ASC41, an oral tablet, liver-targeted prodrug and its active moiety (ASC41-A), a selective thyroid hormone receptor beta (THR-β) agonist.
Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab) is Safe and Well Tolerated in Phase IIa HBV Study prnasia
December 04, 2020
Ascletis Pharma Inc. announces today that Phase IIa data demonstrated that ASC22 (Envafolimab) is safe and well tolerated in chronic hepatitis B (CHB) patients and Phase IIb clinical trial has been initiated. ASC22 (Envafolimab) is a first-in-class ...
Gannex Received U.S. IND Approval for Its NASH Drug Candidate ASC42，an FXR Agonist prnasia
October 16, 2020
Gannex Pharma Co. announces today that it received investigational new drug application (IND) approval from FDA for its drug candidate ASC42, to conduct clinical trials for non-alcoholic steatohepatitis (NASH) indication.

Previous page 1 2 3 4 5 Next page